Neuphoria Therapeutics Inc.
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $15.6M
- Net income
- -$369.6K
- Total assets
- $28.6M
- Market cap
- $24.3M
- Operating margin
- -7.2%
- Net margin
- -2.4%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $15.6M
- Operating expenses
- $16.8M
- Operating income
- -$1.1M
- Income tax
- -$468.4K
- Net income
- -$369.6K
- EPS (basic)
- $-0.23
- EPS (diluted)
- $-0.23
Balance sheet
- Total assets
- $28.6M
- Current assets
- $15.0M
- Total liabilities
- $9.6M
- Current liabilities
- $4.2M
- Shareholders’ equity
- $19.0M
Cash flow
- Operating cash flow
- $77.2K
- Investing cash flow
- -$1.6M
- Financing cash flow
- $1.5M
- Net cash flow
- $3.8K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $24.3M
- EPS (diluted)
- $-0.23
- Shares outstanding
- 5.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 16, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $369.6K in FY2025.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Neuphoria Therapeutics Inc..
Write a review
News about Neuphoria Therapeutics Inc.
News & sentiment via Polygon.io
